In this randomised , open-label , phase 2 study , adult patients with platinum-sensitive , recurrent , high-grade serous ovarian cancer who had received up to three previous courses of platinum-based chemotherapy and who were progression free for at least 6 months before randomisation received either olaparib ( 200 mg capsules twice daily , administered orally on days 1-10 of each 21-day cycle ) plus paclitaxel ( 175 mg/m ( 2 ) , administered intravenously on day 1 ) and carboplatin ( area under the curve [ AUC ] 4 mg/mL per min , according to the Calvert formula , administered intravenously on day 1 ) , then olaparib monotherapy ( 400 mg capsules twice daily , given continuously ) until progression ( the olaparib plus chemotherapy group ) , or paclitaxel ( 175 mg/m ( 2 ) on day 1 ) and carboplatin ( AUC 6 mg/mL per min on day 1 ) then no further treatment ( the chemotherapy alone group ) .